Cactus Announces Timing of Third Quarter 2026 Earnings Release and Conference Call
Get Alerts WHD Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1%
Revenue Growth %: +66.0%
Join SI Premium – FREE
HOUSTON--(BUSINESS WIRE)--
Cactus, Inc. (NYSE: WHD) (“Cactus” or the “Company”) today announced that it will issue its third quarter 2026 earnings release after market close on Wednesday, October 28, 2026. The Company will host a conference call to discuss financial and operational results on Thursday, October 29, 2026 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time).
The call will be webcast on Cactus’ website at www.CactusWHD.com. Please access the webcast at least 10 minutes ahead of the start time to ensure a proper connection. An archived version will be available on the Company’s website shortly after the end of the call.
About Cactus, Inc.
Cactus designs, manufactures, sells or rents a range of highly engineered pressure control and spoolable pipe technologies. Its products are sold and rented principally for onshore unconventional oil and gas wells and are utilized during the drilling, completion and production phases of its customers’ wells. In addition, it provides field services for its products and rental items to assist with the installation, maintenance and handling of the equipment. Cactus operates service centers and manufacturing facilities globally with an emphasis in North America and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261013265976/en/
Cactus, Inc.
Alan Boyd, 713-904-4669
Treasurer, Director of Corporate Development and Investor Relations
[email protected]
Source: Cactus, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Puerto Rico Residents Tax-Free Fund V, Inc. Announces Path to Anticipated Expansion of Shareholder Liquidity Options
- Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
- Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share